相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The effect of fingolimod on focal and diffuse grey matter damage in active MS patients
Albulena Bajrami et al.
JOURNAL OF NEUROLOGY (2018)
Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis
Johannes Lorscheider et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis
Laura Gaetano et al.
NEUROLOGY (2018)
Measurement of Whole-Brain and Gray Matter Atrophy in Multiple Sclerosis: Assessment with MR Imaging
Loredana Storelli et al.
RADIOLOGY (2018)
Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis
Johannes Lorscheider et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis
Fariha Khalid et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2017)
Grey matter atrophy is associated with disability increase in natalizumab-treated patients
Ethel Ciampi et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod
Nils Koch-Henriksen et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Grey matter atrophy is associated with disability increase in natalizumab-treated patients
Ethel Ciampi et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod
Nils Koch-Henriksen et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)
Giancarlo Comi et al.
JOURNAL OF NEUROLOGY (2017)
A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis
Fawad Yousuf et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2017)
Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis
Nicola De Stefano et al.
CNS DRUGS (2017)
Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
Ludwig Kapposl et al.
JOURNAL OF NEUROLOGY (2016)
Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies
Damiano Baroncini et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Comparative efficacy of fingolimod vs natalizumab A French multicenter observational study
Laetitia Barbin et al.
NEUROLOGY (2016)
Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies
Damiano Baroncini et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials
Georgios Tsivgoulis et al.
PLOS ONE (2016)
Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis
Tomas Kalincik et al.
ANNALS OF NEUROLOGY (2015)
Impact of natalizumab treatment on fatigue, mood, and aspects of cognition in relapsing-remitting multiple sclerosis
Annett Kunkel et al.
FRONTIERS IN NEUROLOGY (2015)
Brain atrophy in natalizumab-treated patients: A 3-year follow-up
J. Sastre-Garriga et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings
Flavia Mattioli et al.
PLOS ONE (2015)
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy
Robert L. Carruthers et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Natalizumab may reduce cognitive changes and brain atrophy rate in relapsingremitting multiple sclerosis: a prospective, non-randomized pilot study
E. Portaccio et al.
EUROPEAN JOURNAL OF NEUROLOGY (2013)
Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort
Stefan Braune et al.
JOURNAL OF NEUROLOGY (2013)
Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes
Angela Vidal-Jordana et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis
F. Rinaldi et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Mechanisms of Fingolimod's Efficacy and Adverse Effects in Multiple Sclerosis
Jeffrey A. Cohen et al.
ANNALS OF NEUROLOGY (2011)
Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study
X. Montalban et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis
Ernst-Wilhelm Radue et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS
D. H. Miller et al.
NEUROLOGY (2007)
Immune surveillance in multiple sclerosis patients treated with natalizumab
O Stüve et al.
ANNALS OF NEUROLOGY (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
RA Rudick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
分享论文
